• Profile
Close

Non-persistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: A retrospective cohort study based on German RA patients

Patient Preference and Adherence Aug 12, 2017

Müller S, et al. – The objective of this research was to evaluate the level of nonpersistence (NP) and nonadherence (NA) to methotrexate (MTX) therapy in German patients with rheumatoid arthritis (RA). In one–fourth of German patients with RA, NP to MTX treatment appeared to be common. At least 6.5% patients were also affected by NA. Moreover, a considerable percentage of RA patients who discontinued MTX therapy do not receive any follow–up disease–modifying antirheumatic drug (DMARD) therapy.

Methods

  • RA patients who received a MTX therapy (subgroup: treatment–naive patients) were analyzed, based on German claims data.
  • NP was defined as treatment gap >12 weeks. 
  • Regarding NA, it is the overall medication possession ratio (MPR) during an observational period of 12 or 24 months after therapy.
  • The MPR was calculated only for the periods of therapy continuation.
  • NA was defined as MPR <80%.

Results

  • A total of 7,146 RA patients who received at least one MTX prescription (subgroup: 1,211 treatment–naive patients) could be observed (mean age: 64.4 years, 73.6% female).
  • As per the outcomes, percentage of NP patients among MTX–naive patients after 6, 12 and 18 months was 16.7%, 34.0% and 36.7%, respectively. 
  • After MTX therapy discontinuation, 39.9% had restarted their MTX therapy, 13.8% had received another non–MTX synthetic disease–modifying antirheumatic drug (sDMARD), 8.1% had biological DMARD (bDMARD) and 49.2% had not received any DMARD prescription at all.
  • Overall, 12– and 24–month MPRs for MTX therapy were 83.0% and 76.5% with a percentage of NA patients of 25.8% and 33.8%, respectively. 
  • The percentage of patients with an MPR <80% was 6.5%, during periods of general treatment continuation.

Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay